S
Stephen R. Broderick
Researcher at Johns Hopkins University School of Medicine
Publications - 79
Citations - 7899
Stephen R. Broderick is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 26, co-authored 62 publications receiving 6237 citations. Previous affiliations of Stephen R. Broderick include Mount Sinai St. Luke's and Mount Sinai Roosevelt & Memorial Sloan Kettering Cancer Center.
Papers
More filters
Journal ArticleDOI
Somatic mutations affect key pathways in lung adenocarcinoma
Li Ding,Gad Getz,David A. Wheeler,Elaine R. Mardis,Michael D. McLellan,Kristian Cibulskis,Carrie Sougnez,Heidi Greulich,Heidi Greulich,Donna M. Muzny,Margaret Morgan,Lucinda Fulton,Robert S. Fulton,Qunyuan Zhang,Michael C. Wendl,Michael S. Lawrence,David E. Larson,Ken Chen,David J. Dooling,Aniko Sabo,Alicia Hawes,Hua Shen,Shalini N. Jhangiani,Lora Lewis,Otis Hall,Yiming Zhu,Tittu Mathew,Yanru Ren,Jiqiang Yao,Steven E. Scherer,Kerstin Clerc,Ginger A. Metcalf,Brian Ng,Aleksandar Milosavljevic,Manuel L. Gonzalez-Garay,John R. Osborne,Rick Meyer,Xiaoqi Shi,Yuzhu Tang,Daniel C. Koboldt,Ling Lin,Rachel Abbott,Tracie L. Miner,Craig Pohl,Ginger A. Fewell,Carrie A. Haipek,Heather Schmidt,Brian H. Dunford-Shore,Aldi T. Kraja,Seth D. Crosby,Christopher S. Sawyer,Tammi L. Vickery,Sacha N. Sander,Jody S. Robinson,Wendy Winckler,Wendy Winckler,Jennifer Baldwin,Lucian R. Chirieac,Amit Dutt,Amit Dutt,Timothy Fennell,Megan Hanna,Megan Hanna,Bruce E. Johnson,Robert C. Onofrio,Roman K. Thomas,Giovanni Tonon,Barbara A. Weir,Barbara A. Weir,Xiaojun Zhao,Xiaojun Zhao,Liuda Ziaugra,Michael C. Zody,Thomas J. Giordano,Mark B. Orringer,Jack A. Roth,Margaret R. Spitz,Ignacio I. Wistuba,Bradley A. Ozenberger,Peter J. Good,Andrew C. Chang,David G. Beer,Mark A. Watson,Marc Ladanyi,Stephen R. Broderick,Akihiko Yoshizawa,William D. Travis,William Pao,Michael A. Province,George M. Weinstock,Harold E. Varmus,Stacey Gabriel,Eric S. Lander,Richard A. Gibbs,Matthew Meyerson,Matthew Meyerson,Richard K. Wilson +96 more
TL;DR: Somatic mutations in primary lung adenocarcinoma for several tumour suppressor genes involved in other cancers and for sequence changes in PTPRD as well as the frequently deleted gene LRP1B are found.
Journal ArticleDOI
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Patrick M. Forde,Jamie E. Chaft,Kellie N. Smith,Valsamo Anagnostou,Tricia R. Cottrell,Matthew D. Hellmann,Marianna Zahurak,Stephen C. Yang,David R. Jones,Stephen R. Broderick,Richard J. Battafarano,Moises J. Velez,Natasha Rekhtman,Zachary T. Olah,Jarushka Naidoo,Kristen A. Marrone,Franco Verde,Haidan Guo,Jiajia Zhang,Justina X. Caushi,Hok Yee Chan,John-William Sidhom,Robert B. Scharpf,James R. White,Edward Gabrielson,Hao Wang,Gary L. Rosner,Valerie W. Rusch,Jedd D. Wolchok,Taha Merghoub,Janis M. Taube,Victor E. Velculescu,Suzanne L. Topalian,Julie R. Brahmer,Drew M. Pardoll +34 more
TL;DR: Nivolumab was associated with few side effects, did not delay surgery, and induced a major pathological response in 45% of resected tumors, and the tumor mutational burden was predictive of the pathological response to PD‐1 blockade.
Journal ArticleDOI
Characterizing the cancer genome in lung adenocarcinoma
Barbara A. Weir,Barbara A. Weir,Michele S. Woo,Gad Getz,Sven Perner,Sven Perner,Li Ding,Rameen Beroukhim,Rameen Beroukhim,William M. Lin,William M. Lin,Michael A. Province,Aldi T. Kraja,Laura A. Johnson,Kinjal Shah,Kinjal Shah,Mitsuo Sato,Roman K. Thomas,Justine A. Barletta,Ingrid B. Borecki,Stephen R. Broderick,Andrew C. Chang,Derek Y. Chiang,Derek Y. Chiang,Lucian R. Chirieac,Jeonghee Cho,Yoshitaka Fujii,Adi F. Gazdar,Thomas J. Giordano,Heidi Greulich,Heidi Greulich,Megan Hanna,Megan Hanna,Bruce E. Johnson,Mark G. Kris,Alex E. Lash,Ling Lin,Neal I. Lindeman,Elaine R. Mardis,John Douglas Mcpherson,John D. Minna,Margaret Morgan,Mark Nadel,Mark Nadel,Mark B. Orringer,John R. Osborne,Brad Ozenberger,Alex H. Ramos,Alex H. Ramos,James T. Robinson,Jack A. Roth,Valerie W. Rusch,Hidefumi Sasaki,Frances A. Shepherd,Carrie Sougnez,Margaret R. Spitz,Ming-Sound Tsao,David Twomey,Roel G.W. Verhaak,George M. Weinstock,David A. Wheeler,Wendy Winckler,Wendy Winckler,Akihiko Yoshizawa,Soyoung Yu,Maureen F. Zakowski,Qunyuan Zhang,David G. Beer,Ignacio I. Wistuba,Mark A. Watson,Levi A. Garraway,Levi A. Garraway,Marc Ladanyi,William D. Travis,William Pao,Mark A. Rubin,Mark A. Rubin,Stacey Gabriel,Richard A. Gibbs,Harold E. Varmus,Richard K. Wilson,Eric S. Lander,Eric S. Lander,Eric S. Lander,Matthew Meyerson,Matthew Meyerson +85 more
TL;DR: A large-scale project to characterize copy-number alterations in primary lung adenocarcinomas using dense single nucleotide polymorphism arrays identifies NKX2-1 (NK2 homeobox 1, also called TITF1), which lies in the minimal 14q13.3 amplification interval and encodes a lineage-specific transcription factor, as a novel candidate proto-oncogene involved in a significant fraction of lung carcinomas.
Journal ArticleDOI
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
Patrick M. Forde,Jonathan Spicer,Shun Lu,Mariano Provencio,Tetsuya Mitsudomi,Mark M. Awad,Enriqueta Felip,Stephen R. Broderick,Julie R. Brahmer,J. Swanson,Keith M. Kerr,Changli Wang,Tudor Ciuleanu,Gene Brian Saylors,Fumihiro Tanaka,Hiroyuki Ito,Keke Chen,Moishe Liberman,Everett E. Vokes,Janis M. Taube,C. Dorange,Jun Bo Cai,Joseph Fiore,Anthony Jarkowski,David Balli,Mark Sausen,Dimple Pandya,Christophe Y Calvet,Nicolas Girard +28 more
TL;DR: In patients with resectable NSCLC, neoadjuvant nivolumab plus chemotherapy resulted in significantly longer event-free survival and a higher percentage of patients with a pathological complete response than chemotherapy alone.
Journal ArticleDOI
Opioid-Prescribing Guidelines for Common Surgical Procedures: An Expert Panel Consensus
Heidi N. Overton,Marie N. Hanna,William E. Bruhn,Susan Hutfless,Mark C. Bicket,Mark C. Bicket,Martin A. Makary,Martin A. Makary,Brian R. Matlaga,Clark T. Johnson,Jeanne S. Sheffield,Ronen Shechter,Hien Nguyen,Greg Osgood,Christi Walsh,Richard A. Burkhart,Alex B. Blair,Wes Ludwig,Suzanne A. Nesbit,Peiqi Wang,Suzette Morgan,Christian Jones,Lisa M. Kodadek,James Taylor,Zachary Obinna Enumah,Richard C. Gilmore,Mehran Habibi,Kayode Williams,Jon Russell,Karen Wang,Joanna W. Etra,Stephen R. Broderick,Tiffany Zavadsky +32 more
TL;DR: In this paper, a 3-step modified Delphi method involving a multidisciplinary expert panel of 6 relevant stakeholder groups (surgeons, pain specialists, outpatient surgical nurse practitioners, surgical residents, patients, and pharmacists) was used to develop consensus ranges for outpatient opioid prescribing at the time of discharge after 20 common procedures in 8 surgical specialties.